-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of March 21, more than 100 pharmaceutical companies have released performance reports
.
Among them, Zhifei Bio, Rejing Bio, Ascentage Pharmaceutical, Vibration Pharmaceutical and other companies performed well
.
For example, Zhifei Bio’s net profit in 2021 will increase by 208.
88% year-on-year to 10.
197 billion yuan; its operating income will increase by 101.
68% year-on-year to 30.
637 billion yuan
.
In 2021, Rejing Bio’s net profit increased by 1856.
81% year-on-year to 2.
193 billion yuan; its operating income increased by 946.
14% year-on-year to 5.
372 billion yuan
.
In 2021, Ascentage Pharma will achieve a year-on-year increase of 123.
2% in operating income to RMB 27.
91 million
.
Zhendong Pharmaceutical's net profit attributable to the parent company in 2021 will increase by 903.
37% year-on-year to 2.
629 billion yuan; operating income will increase by 5.
05% year-on-year to 5.
093 billion yuan
.
In addition, the net profit of Orient Bio, Wantai Bio, and Zuoli Pharmaceutical in 2021 will all increase by more than 100% year-on-year
.
For the growth of performance, increasing investment in research and development is an important driving force for many companies
.
For example, Zhifei Bio said that the company has increased investment in research and development to introduce new products, and the sales of independent products and agency products have continued to increase steadily
.
In answering questions from investors recently, the company also stated that the company adheres to the "technology + market" two-wheel-driven development model, and attaches great importance to the building and improvement of R&D innovation capabilities
.
With stable capital investment and personnel investment, the matrix layout of vaccine products is carried out through diversified development platforms to promote the long-term stable development of the company.
The company has 26 research projects, involving the prevention of tuberculosis, meningitis, pneumonia, influenza, rabies and other human vaccines Projects and products have a clear echelon structure and rich levels
.
Rujing Bio also stated in the investor interaction platform recently that the company has always regarded innovation as one of its core competitiveness.
After years of research and investment, it has established a number of innovative technology platforms, with a number of cutting-edge innovative technologies and innovative products; With clinical POCT Beijing Key Laboratory, Beijing Enterprise Technology Center, Postdoctoral Research Station, etc.
.
Ascentage Pharma will continue to increase its investment in innovation in 2021, and its annual R&D expenditure will increase by 35.
8% year-on-year to RMB 767 million
.
It is reported that in 2021, Ascentage Pharma will make great progress in clinical development and external cooperation under the guidance of the "Global Innovation" strategy; Tini (trade name: Nerlik) was officially approved for sale in China, marking the successful leap of Ascentage Pharma from a research and development-oriented enterprise to an enterprise with commercialization capabilities and a new journey of commercialization
.
According to relevant statistics, companies with high performance in 2021 will focus on CXO and vaccines.
In addition, medical equipment companies have also maintained steady growth
.
It is estimated that companies with a growth rate of more than 100% include Proton, Asymchem, Kangtai Bio, etc.
; companies with a growth rate of more than 50% include WuXi AppTec, Tigermed, etc.
; companies with a growth rate of more than 30% There are Xinmai Medical, Kanglong Chemical, Jianfan Bio, Pumen Technology, Jinyu Medical, etc.
; companies with a performance growth rate of more than 20% include Kaili Medical, Haitai Xinguang, Mindray Medical, Antu Bio, Health Yuan, Wuwu Biology, Pien Tze Huang,
etc.
In 2021, many companies in the pharmaceutical field will achieve good performance growth
.
It is reported that as the market enters the first quarter, many listed companies have also disclosed their performance.
Among them, the pharmaceutical industry is expected to see a quarter-on-quarter improvement in the performance of the sector in the first quarter due to the dual factors of normalized epidemic prevention and control and the opening of overseas channels
.
Some analysts believe that CXO, equipment, vaccines, traditional Chinese medicine and other sectors are expected to achieve rapid growth in the first quarter
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, Zhifei Bio, Rejing Bio, Ascentage Pharmaceutical, Vibration Pharmaceutical and other companies performed well
.
For example, Zhifei Bio’s net profit in 2021 will increase by 208.
88% year-on-year to 10.
197 billion yuan; its operating income will increase by 101.
68% year-on-year to 30.
637 billion yuan
.
In 2021, Rejing Bio’s net profit increased by 1856.
81% year-on-year to 2.
193 billion yuan; its operating income increased by 946.
14% year-on-year to 5.
372 billion yuan
.
In 2021, Ascentage Pharma will achieve a year-on-year increase of 123.
2% in operating income to RMB 27.
91 million
.
Zhendong Pharmaceutical's net profit attributable to the parent company in 2021 will increase by 903.
37% year-on-year to 2.
629 billion yuan; operating income will increase by 5.
05% year-on-year to 5.
093 billion yuan
.
In addition, the net profit of Orient Bio, Wantai Bio, and Zuoli Pharmaceutical in 2021 will all increase by more than 100% year-on-year
.
For the growth of performance, increasing investment in research and development is an important driving force for many companies
.
For example, Zhifei Bio said that the company has increased investment in research and development to introduce new products, and the sales of independent products and agency products have continued to increase steadily
.
In answering questions from investors recently, the company also stated that the company adheres to the "technology + market" two-wheel-driven development model, and attaches great importance to the building and improvement of R&D innovation capabilities
.
With stable capital investment and personnel investment, the matrix layout of vaccine products is carried out through diversified development platforms to promote the long-term stable development of the company.
The company has 26 research projects, involving the prevention of tuberculosis, meningitis, pneumonia, influenza, rabies and other human vaccines Projects and products have a clear echelon structure and rich levels
.
Rujing Bio also stated in the investor interaction platform recently that the company has always regarded innovation as one of its core competitiveness.
After years of research and investment, it has established a number of innovative technology platforms, with a number of cutting-edge innovative technologies and innovative products; With clinical POCT Beijing Key Laboratory, Beijing Enterprise Technology Center, Postdoctoral Research Station, etc.
.
Ascentage Pharma will continue to increase its investment in innovation in 2021, and its annual R&D expenditure will increase by 35.
8% year-on-year to RMB 767 million
.
It is reported that in 2021, Ascentage Pharma will make great progress in clinical development and external cooperation under the guidance of the "Global Innovation" strategy; Tini (trade name: Nerlik) was officially approved for sale in China, marking the successful leap of Ascentage Pharma from a research and development-oriented enterprise to an enterprise with commercialization capabilities and a new journey of commercialization
.
According to relevant statistics, companies with high performance in 2021 will focus on CXO and vaccines.
In addition, medical equipment companies have also maintained steady growth
.
It is estimated that companies with a growth rate of more than 100% include Proton, Asymchem, Kangtai Bio, etc.
; companies with a growth rate of more than 50% include WuXi AppTec, Tigermed, etc.
; companies with a growth rate of more than 30% There are Xinmai Medical, Kanglong Chemical, Jianfan Bio, Pumen Technology, Jinyu Medical, etc.
; companies with a performance growth rate of more than 20% include Kaili Medical, Haitai Xinguang, Mindray Medical, Antu Bio, Health Yuan, Wuwu Biology, Pien Tze Huang,
etc.
In 2021, many companies in the pharmaceutical field will achieve good performance growth
.
It is reported that as the market enters the first quarter, many listed companies have also disclosed their performance.
Among them, the pharmaceutical industry is expected to see a quarter-on-quarter improvement in the performance of the sector in the first quarter due to the dual factors of normalized epidemic prevention and control and the opening of overseas channels
.
Some analysts believe that CXO, equipment, vaccines, traditional Chinese medicine and other sectors are expected to achieve rapid growth in the first quarter
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
